Publikation: TRAIL-induced apoptosis : between tumor therapy and immunopathology
Lade...
Dateien
Datum
2009
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
URI (zitierfähiger Link)
DOI (zitierfähiger Link)
Internationale Patentnummer
Link zur Lizenz
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Open Access Green
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published
Erschienen in
Annals of the New York Academy of Sciences. 2009, 1171(1), pp. 50-58. ISSN 0077-8923. eISSN 1749-6632. Available under: doi: 10.1111/j.1749-6632.2009.04905.x
Zusammenfassung
The death ligand members of the tumor necrosis factor (TNF) family are potent inducers of apoptosis in a variety of cell types. In particular, TNF-related apoptosis-inducing ligand (TRAIL) has recently received much scientific and commercial attention because of its potent tumor cell-killing activity while leaving normal untransformed cells mostly unaffected. Furthermore, TRAIL strongly synergizes with conventional chemotherapeutic drugs in inducing tumor cell apoptosis, making it a most promising candidate for future cancer therapy. Increasing evidence indicates, however, that TRAIL may also induce or modulate apoptosis in primary cells. A particular concern is the potential side effect of TRAIL-based tumor therapies in the liver. In this review we summarize some of the recent findings on the role of TRAIL in tumor cell and hepatocyte apoptosis.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
570 Biowissenschaften, Biologie
Schlagwörter
TRAIL, hepatocyte, apoptosis, tumor, liver injury, Bim, Jun kinase
Konferenz
Rezension
undefined / . - undefined, undefined
Zitieren
ISO 690
CORAZZA, Nadia, Daniela KASSAHN, Sabine JAKOB, Anastasia BADMANN, Thomas BRUNNER, 2009. TRAIL-induced apoptosis : between tumor therapy and immunopathology. In: Annals of the New York Academy of Sciences. 2009, 1171(1), pp. 50-58. ISSN 0077-8923. eISSN 1749-6632. Available under: doi: 10.1111/j.1749-6632.2009.04905.xBibTex
@article{Corazza2009-08TRAIL-14347,
year={2009},
doi={10.1111/j.1749-6632.2009.04905.x},
title={TRAIL-induced apoptosis : between tumor therapy and immunopathology},
number={1},
volume={1171},
issn={0077-8923},
journal={Annals of the New York Academy of Sciences},
pages={50--58},
author={Corazza, Nadia and Kassahn, Daniela and Jakob, Sabine and Badmann, Anastasia and Brunner, Thomas}
}RDF
<rdf:RDF
xmlns:dcterms="http://purl.org/dc/terms/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:bibo="http://purl.org/ontology/bibo/"
xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
xmlns:foaf="http://xmlns.com/foaf/0.1/"
xmlns:void="http://rdfs.org/ns/void#"
xmlns:xsd="http://www.w3.org/2001/XMLSchema#" >
<rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/14347">
<dc:creator>Jakob, Sabine</dc:creator>
<dc:creator>Badmann, Anastasia</dc:creator>
<dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
<dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/14347/2/Corazza_ANYACAD_09.pdf"/>
<dc:contributor>Kassahn, Daniela</dc:contributor>
<dc:contributor>Badmann, Anastasia</dc:contributor>
<dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/14347/2/Corazza_ANYACAD_09.pdf"/>
<foaf:homepage rdf:resource="http://localhost:8080/"/>
<dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
<dc:creator>Kassahn, Daniela</dc:creator>
<dcterms:issued>2009-08</dcterms:issued>
<dcterms:abstract xml:lang="eng">The death ligand members of the tumor necrosis factor (TNF) family are potent inducers of apoptosis in a variety of cell types. In particular, TNF-related apoptosis-inducing ligand (TRAIL) has recently received much scientific and commercial attention because of its potent tumor cell-killing activity while leaving normal untransformed cells mostly unaffected. Furthermore, TRAIL strongly synergizes with conventional chemotherapeutic drugs in inducing tumor cell apoptosis, making it a most promising candidate for future cancer therapy. Increasing evidence indicates, however, that TRAIL may also induce or modulate apoptosis in primary cells. A particular concern is the potential side effect of TRAIL-based tumor therapies in the liver. In this review we summarize some of the recent findings on the role of TRAIL in tumor cell and hepatocyte apoptosis.</dcterms:abstract>
<dc:creator>Corazza, Nadia</dc:creator>
<dc:contributor>Corazza, Nadia</dc:contributor>
<dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
<void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
<dc:rights>terms-of-use</dc:rights>
<dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-10-26T07:43:35Z</dcterms:available>
<dc:contributor>Brunner, Thomas</dc:contributor>
<dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-10-26T07:43:35Z</dc:date>
<dc:language>eng</dc:language>
<dc:contributor>Jakob, Sabine</dc:contributor>
<dcterms:title>TRAIL-induced apoptosis : between tumor therapy and immunopathology</dcterms:title>
<dc:creator>Brunner, Thomas</dc:creator>
<dcterms:bibliographicCitation>First publ. in: Annals of the New York Acadamy of Sciences ; 1171 (2009). - pp. 50-58</dcterms:bibliographicCitation>
<bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/14347"/>
</rdf:Description>
</rdf:RDF>Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Nein
